Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping

@inproceedings{Beck2016EstimationOT,
  title={Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping},
  author={H. Beck and Rahel Wampfler and Nick Carter and Gavin C. K. W. Koh and Lyda Os{\'o}rio and Ronnatrai Rueangweerayut and Srivcha Krudsood and Marcus Vin{\'i}cius Guimar{\~a}es de Lacerda and Alejandro Llanos-Cuentas and Stephan Duparc and Justin P. Rubio and Justin Anton Green},
  booktitle={The Journal of infectious diseases},
  year={2016}
}
UNLABELLED Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine… CONTINUE READING
Highly Cited
This paper has 25 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS
13 Citations
14 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Genetic diversity of Plasmodium vivax over time and space: a community-based study in rural Amazonia

  • CL Batista, S Barbosa, M Da Silva Bastos, SA Viana, MU. Ferreira
  • Parasitology
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…